The German vaccine developer CureVac GmbH has secured a licensing agreement with Janssen Pharmaceuticals (Johnson & Johnson Inc) to develop an influenza vaccine based on its messenger RNA technology. Financial terms were not disclosed. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
